User profiles for Askin Gülsen

Askin Gulsen

Heinrich Heine University Düsseldorf
Verified email at uksh.de
Cited by 527

[HTML][HTML] The effect of smoking on COVID-19 symptom severity: systematic review and meta-analysis

A Gülsen, BA Yigitbas, B Uslu, D Drömann… - Pulmonary …, 2020 - hindawi.com
Background. Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SAR2-COV-2) and was first identified in Wuhan, China, in …

[HTML][HTML] Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events

A Gülsen, B Wedi, U Jappe - Allergo journal international, 2020 - Springer
Purpose Biotechnological substances (BSs) are strongly relied upon to prevent rejection of
transplanted organs, and to treat oncological, allergological, and other inflammatory diseases…

Specific IgE against the house dust mite allergens Der p 5, 20 and 21 influences the phenotype and severity of atopic diseases

…, M Böttger, S Traidl, C Schwager, A Gülsen… - Allergy, 2023 - Wiley Online Library
Background House dust mites (HDM) are among the most important sources for airborne
allergens with high relevance for atopic diseases. Routine tests contain only 4 of 32 registered …

Effect of comorbid pulmonary disease on the severity of COVID‐19: a systematic review and meta‐analysis

A Gülsen, IR König, U Jappe, D Drömann - Respirology, 2021 - Wiley Online Library
Coronavirus disease 2019 (COVID‐19) caused by infection with severe acute respiratory
syndrome coronavirus 2 was first detected in Wuhan, China, in late 2019 and continues to …

[HTML][HTML] Biologics for atopic diseases: Indication, side effect management, and new developments

U Jappe, H Beckert, KC Bergmann, A Gülsen… - Allergologie …, 2021 - ncbi.nlm.nih.gov
With the advent of biologicals, more and more therapeutics are available that specifically
address specific switch points in the pathomechanism of immunologically dominated diseases. …

[HTML][HTML] Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches

A Gülsen, B Wedi, U Jappe - Allergo Journal International, 2020 - Springer
Purpose Biotechnological substances (BS) have rapidly expanded their clinical use. In
parallel, there is an increase in expected or unexpected immunological or non-immunological …

[HTML][HTML] Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis

A Gülsen, F Ruëff, U Jappe - Allergologie Select, 2021 - ncbi.nlm.nih.gov
Background: Systemic reactions and anaphylaxis due to Hymenoptera venoms occur in up
to 7.5% of the European population. Fatal sting reactions are very rare. Serum tryptase levels …

[HTML][HTML] Bronchoscopic lung volume reduction: a 2018 review and update

A Gülşen - Turkish Thoracic Journal, 2018 - ncbi.nlm.nih.gov
Bronchoscopic lung volume reduction (BLVR) procedure has expanded the treatment
spectrum of patients with end-stage emphysema. These treatments include valve, coil, thermal …

Combination of immunotherapies for severe allergic asthma

A Gülsen, S Wallis, U Jappe - Journal of Asthma, 2021 - Taylor & Francis
Introduction Difficult-to-treat or severe persistent asthma accounts for 5–10% of the asthma
population worldwide. However, this group of patients creates a higher burden on health …

[HTML][HTML] Air exposure and cell differentiation are essential for investigation of SARS-CoV-2 entry genes in human primary airway epithelial cells in vitro

B Kasper, X Yue, T Goldmann, A Gülsen… - Frontiers in …, 2022 - frontiersin.org
Background: In-vitro models of differentiated primary human airway epithelial cells are a
valuable tool to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. …